secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0000014272-23-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Q4 revenue $11.4B, GAAP EPS $0.95; full-year $46.2B, EPS $2.95; in-line/new product portfolio grows 7%
--------------------------------------------------------------------------------

- Q4 2022 revenues $11,406M (-5% YoY); full-year $46,159M (flat YoY).
- GAAP EPS: Q4 $0.95, full-year $2.95; Non-GAAP EPS: Q4 $1.82, full-year $7.70.
- In-Line and New Product Portfolio revenues up 7% (12% ex-FX) Q4; full-year up 9% (13% ex-FX).
- Revlimid revenues declined 32% Q4 and 22% full-year due to loss of exclusivity.
- 2023 GAAP and non-GAAP guidance provided reflecting continued revenue and earnings growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427223000018/0000014272-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427223000018/bmy-20230202.htm
  HTML page:      https://secwatch.observer/filing/0000014272-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer